Free Trial

Biomea Fusion (BMEA) Competitors

Biomea Fusion logo
$8.88 -0.03 (-0.34%)
(As of 11/6/2024 ET)

BMEA vs. EPZM, CHMA, ABOS, PRTK, OVID, XNCR, RCUS, NTLA, EVO, and ARDX

Should you be buying Biomea Fusion stock or one of its competitors? The main competitors of Biomea Fusion include Epizyme (EPZM), Chiasma (CHMA), Acumen Pharmaceuticals (ABOS), Paratek Pharmaceuticals (PRTK), Ovid Therapeutics (OVID), Xencor (XNCR), Arcus Biosciences (RCUS), Intellia Therapeutics (NTLA), Evotec (EVO), and Ardelyx (ARDX). These companies are all part of the "medical" sector.

Biomea Fusion vs.

Epizyme (NASDAQ:EPZM) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, community ranking, analyst recommendations and earnings.

Biomea Fusion has lower revenue, but higher earnings than Epizyme. Biomea Fusion is trading at a lower price-to-earnings ratio than Epizyme, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Epizyme$37.43M6.61-$251.12M-$1.72-0.85
Biomea FusionN/AN/A-$117.25M-$4.01-2.21

Biomea Fusion has a net margin of 0.00% compared to Epizyme's net margin of -391.90%. Biomea Fusion's return on equity of -118.90% beat Epizyme's return on equity.

Company Net Margins Return on Equity Return on Assets
Epizyme-391.90% -2,459.33% -69.74%
Biomea Fusion N/A -118.90%-93.66%

Biomea Fusion has a consensus price target of $30.50, indicating a potential upside of 243.47%. Given Biomea Fusion's stronger consensus rating and higher possible upside, analysts clearly believe Biomea Fusion is more favorable than Epizyme.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Epizyme
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Biomea Fusion
0 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
3.00

76.5% of Epizyme shares are owned by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are owned by institutional investors. 23.4% of Epizyme shares are owned by insiders. Comparatively, 27.6% of Biomea Fusion shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Epizyme has a beta of -0.41, indicating that its stock price is 141% less volatile than the S&P 500. Comparatively, Biomea Fusion has a beta of -0.41, indicating that its stock price is 141% less volatile than the S&P 500.

In the previous week, Biomea Fusion had 14 more articles in the media than Epizyme. MarketBeat recorded 14 mentions for Biomea Fusion and 0 mentions for Epizyme. Biomea Fusion's average media sentiment score of 0.36 beat Epizyme's score of 0.22 indicating that Biomea Fusion is being referred to more favorably in the news media.

Company Overall Sentiment
Epizyme Neutral
Biomea Fusion Neutral

Epizyme received 427 more outperform votes than Biomea Fusion when rated by MarketBeat users. However, 65.79% of users gave Biomea Fusion an outperform vote while only 60.69% of users gave Epizyme an outperform vote.

CompanyUnderperformOutperform
EpizymeOutperform Votes
477
60.69%
Underperform Votes
309
39.31%
Biomea FusionOutperform Votes
50
65.79%
Underperform Votes
26
34.21%

Summary

Biomea Fusion beats Epizyme on 12 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BMEA vs. The Competition

MetricBiomea FusionPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$321.81M$6.95B$5.29B$8.82B
Dividend YieldN/A7.97%5.16%4.03%
P/E Ratio-2.218.73116.1516.49
Price / SalesN/A418.54671.85102.53
Price / CashN/A22.5534.9631.66
Price / Book1.875.514.714.66
Net Income-$117.25M$154.22M$114.90M$224.13M
7 Day Performance-14.12%0.31%2.07%2.20%
1 Month Performance-15.27%16.28%7.99%6.23%
1 Year Performance-4.10%41.91%38.33%32.04%

Biomea Fusion Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BMEA
Biomea Fusion
3.8307 of 5 stars
$8.88
-0.3%
$30.50
+243.5%
-11.7%$321.81MN/A-2.2150Analyst Revision
Gap Up
EPZM
Epizyme
N/A$1.47
flat
N/A+0.0%$247.44M$37.43M-0.85250
CHMA
Chiasma
N/A$3.76
flat
N/A+0.0%$217.68M$1.11M-2.3485
ABOS
Acumen Pharmaceuticals
3.4011 of 5 stars
$2.88
-5.0%
N/A+37.0%$182.04MN/A-2.5751Upcoming Earnings
News Coverage
PRTK
Paratek Pharmaceuticals
N/A$2.23
+1.8%
N/A+0.0%$127.82M$160.27M-2.03268High Trading Volume
OVID
Ovid Therapeutics
4.2023 of 5 stars
$1.13
-1.7%
N/A-65.0%$81.62M$390,000.00-2.6360Upcoming Earnings
XNCR
Xencor
4.004 of 5 stars
$21.01
0.0%
N/A+16.6%$1.47B$168.34M-7.27280News Coverage
RCUS
Arcus Biosciences
2.9147 of 5 stars
$15.30
-4.4%
N/A-6.6%$1.46B$117M-4.95500Analyst Forecast
News Coverage
Gap Up
NTLA
Intellia Therapeutics
4.4406 of 5 stars
$14.22
-0.8%
N/A-46.3%$1.46B$36.28M-2.59600Upcoming Earnings
Gap Up
EVO
Evotec
2.5583 of 5 stars
$3.87
-2.3%
N/A-51.3%$1.40B$845.74M0.005,061News Coverage
Gap Down
ARDX
Ardelyx
4.2472 of 5 stars
$5.87
-0.3%
N/A+42.3%$1.39B$124.46M-21.74267Analyst Forecast
Insider Selling
Analyst Revision
Gap Up
High Trading Volume

Related Companies and Tools


This page (NASDAQ:BMEA) was last updated on 11/6/2024 by MarketBeat.com Staff
From Our Partners